Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clini

How the Israel-Iran war may develop

Author6 minutes ago 0

Amazon’s $20bn push into orbit targets SpaceX and China

Author19 minutes ago 0

How to build the right corporate culture

Author32 minutes ago 0

EU plans ban on new Russian gas contracts using trade law

Author34 minutes ago 0